Please login to the form below

Not currently logged in
Email:
Password:

Partner for Sanofi on pneumonia KB001

KaloBios has announced an agreement with Sanofi Pasteur for the development of KB001 for Pseudomonas aeruginosa (Pa) infections

KaloBios Pharmaceuticals has announced an agreement with Sanofi Pasteur for the development and commercialisation of KB001 for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections.

Sanofi Pasteur (the vaccines division of the sanofi-aventis Group), will be responsible for the development and commercialisation of KB001, an investigational new biologic, and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

KaloBios will focus on developing and commercialising KB001 for use in treating patients with cystic fibrosis and bronchiectasis, an obstructive lung disease aggravated by bacterial infections.

Under the terms of the agreement, KaloBios will receive an upfront payment of $35m from Sanofi Pasteur, plus development, regulatory and commercial milestones for a potential further $255m, as well as royalties on eventual product sales. Sanofi Pasteur also has the option to acquire commercial rights to KaloBios' indications for KB001 outside the US and co-promotion rights in the US.

"Hospital-based pneumonias, especially those associated with mechanically ventilated patients in the ICU, are a life-threatening complication that can significantly increase mortality and morbidity as well as add tens of thousands of dollars to the cost of a hospital stay," said Dr Tillman Pearce, chief medical officer of KaloBios.

"KB001's novel mechanism of action against Pa provides a unique means of fighting these infections, which are often resistant to antibiotic therapies. We also think this novel mechanism could have a significant impact on Pseudomonas aeruginosa infections in cystic fibrosis patients as well."

11th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics